EQS-News: Marinomed Biotech AG: Annual General Meeting elects Dr. Eva Hofstädter-Thalmann as a new member of the Supervisory Board

EQS-News: Marinomed Biotech AG / Key word(s): AGM/EGM
   Marinomed Biotech AG: Annual General Meeting elects Dr. Eva
   Hofstädter-Thalmann as a new member of the Supervisory Board

   21.06.2023 / 17:00 CET/CEST
   The issuer is solely responsible for the content of this announcement.

   ══════════════════════════════════════════════════════════════════════════

   Marinomed Biotech AG: Annual General Meeting elects Dr. Eva
   Hofstädter-Thalmann as a new member of the Supervisory Board

     • Industry expert Dr. Eva Hofstädter-Thalmann complements high-profile
       Supervisory Board
     • Dr. Simon Nebel and Mag. Brigitte Ederer reappointed
     • Current female representation on Supervisory Board reaches at 60%

   Korneuburg, Austria, 21 June 2023 – At today’s 6^th Annual General Meeting
   of Marinomed Biotech AG (VSE:MARI), Dr. Eva Hofstädter-Thalmann was newly
   elected to the Company’s Supervisory Board. The Chairman of the
   Supervisory Board, Dr. Simon Nebel, as well as Mag. Brigitte Ederer, whose
   mandates ended rotationally, were reappointed for four years. Ute Lassnig
   and Dr. Gernot Hofer did not stand for re-election, thus the Supervisory
   Board of Marinomed Biotech AG now consists of Dr. Simon Nebel, Brigitte
   Ederer, Dr. Elisabeth Lackner, Ulrich Kinzel and Dr. Eva
   Hofstädter-Thalmann. As a result, the female representation on Marinomed’s
   Supervisory Board now stands at 60%.

   Dr. Eva Hofstädter-Thalmann, who holds a doctorate in biochemistry, spent
   more than 30 years in the pharmaceutical industry, working for Johnson &
   Johnson and Janssen in several commercial and medical affairs leadership
   positions with an increasing global responsibility. Her tasks extended to
   the areas of oncology, hematology and virology. In addition to her
   professional activities, she has been involved in medical education in the
   pharmaceutical industry for many years. Currently, she is the President of
   the Global Alliance of Medical Education (GAME) and member of the Board of
   Directors of the Journal of European Continuing Medical Education (JECME).
   Eva Hofstädter-Thalmann has been working as an independent consultant in
   healthcare with a focus on strategic stakeholder management for the
   pharmaceutical industry as well as for international medical companies
   since the beginning of 2023.

   Dr. Simon Nebel, Chairman of the Supervisory Board: „We are very pleased
   to welcome Eva Hofstädter-Thalmann, a renowned and globally well-connected
   pharmaceutical expert to Marinomed's Supervisory Board. I am very much
   looking forward to our cooperation. At the same time, I would like to
   express my appreciation to Ute Lassnig and Gernot Hofer for their valuable
   commitment over the past years.“

   At the 6^th Annual General Meeting, the Management Board was also
   authorized to increase the Company’s share capital by up to EUR 759,583 by
   June 20, 2028, with the option of partial or total exclusion of
   subscription rights ("Authorized Capital 2023”).

   All further resolutions proposed by the Management Board and the
   Supervisory Board were approved with a large majority.

   Further information on the Annual General Meeting including the voting
   results, the Management Board presentation and the CVs of the Supervisory
   Board members can be found in the investors section of the corporate
   website at:
   [1]https://www.marinomed.com/en/investors-esg/annual-general-meeting.

   About Marinomed Biotech AG

   Marinomed Biotech AG is an Austrian, science-based biotech company with a
   growing development pipeline and globally marketed therapeutics. The
   Company develops innovative patent-protected products in the therapeutic
   areas immunology and virology based on the platform Marinosolv® and the
   virus-blocking activity of iota-carrageenan. The Marinosolv® technology
   improves the solubility and bioavailability of hardly soluble compounds
   and is used to develop new therapeutics for autoreactive immune disorders.
   The virology segment includes Carragelose®-based over-the-counter (OTC)
   products to prevent and treat respiratory viral infections that are
   partnered in more than 40 countries. The Company is headquartered in
   Korneuburg, Austria, and is listed on the prime market of the Vienna Stock
   Exchange (VSE:MARI). For further information, please visit:
   https://www.marinomed.com.

   For further inquiries contact:

   Marinomed Biotech AG        International Media Contact
   PR: Lucia Ziegler           Metrum Communications: Roland Mayrl
   T: +43 2262 90300 158       T: +43 664 6126228
   E-Mail: [2][email protected] E-Mail: [4][email protected]
   IR: Stephanie Kniep          
   T: +43 2262 90300 226
   E-Mail: [3][email protected]

   Disclaimer

   This press release contains forward-looking statements, which are based on
   current views, expectations and projections of the management of Marinomed
   Biotech AG about future events. These forward-looking statements are
   subject to risks, uncertainties and assumptions that could cause actual
   results, performance or events to differ materially from those described
   in, or expressed or implied by, such statements. The current views,
   expectations and projections of the management of Marinomed Biotech AG may
   be identified by the context of such statements or words such as
   “anticipate,” “believe”, “estimate”, “expect”, “intend”, “plan”, “project”
   and “target”. Forward-looking statements are only valid as of the date
   they are made and Marinomed Biotech AG does not assume any obligation to
   update, review or revise any forward-looking statements contained in this
   press release whether as a result of new information, future developments
   or otherwise. Marinomed, Marinosolv® and Carragelose® are registered
   trademarks of Marinomed Biotech AG. These trademarks may be owned or
   licensed in select locations only.

   ══════════════════════════════════════════════════════════════════════════

   21.06.2023 CET/CEST This Corporate News was distributed by EQS Group AG.
   www.eqs.com

   ══════════════════════════════════════════════════════════════════════════

   Language:    English
   Company:     Marinomed Biotech AG
                Hovengasse 25
                2100 Korneuburg
                Austria
   Phone:       +43 2262 90300
   E-mail:      [email protected]
   Internet:    www.marinomed.com
   ISIN:        ATMARINOMED6
   WKN:         A2N9MM
   Listed:      Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt,
                Munich, Stuttgart, Tradegate Exchange; Vienna Stock Exchange
                (Official Market)
   EQS News ID: 1662565


    
   End of News EQS News Service


   1662565  21.06.2023 CET/CEST

References

   Visible links
   1. https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=redirect&url=cfb52b1a8774a6260659353b50085997&application_id=1662565&site_id=apa_ots_austria&application_name=news
   2. mailto:[email protected]
   3. mailto:[email protected]
   4. mailto:[email protected]

OTS-ORIGINALTEXT PRESSEAUSSENDUNG UNTER AUSSCHLIESSLICHER INHALTLICHER VERANTWORTUNG DES AUSSENDERS - WWW.OTS.AT |

print